By 2050, the number of people with diabetes could top 1.3 billion, according to a recent estimate. Obesity and diabetes are huge health concerns for global economies. Novo Nordisk‘s (NYSE: NVO) Ozempic has been a popular drug that’s helped people shed significant body weight, even though the diabetes drug isn’t approved to treat obesity.
But what’s exciting is that the drug’s potential could go far beyond just that. Here’s what investors should know.
What makes Ozempic and Wegovy, which is approved for chronic weight management, effective in helping people lose weight is that they curb cravings. These drugs target the glucagon-like peptide-1 (GLP-1) receptor, which responds to food intake. By doing so, GLP-1 drugs can help reduce cravings. And according to a report from the Wall Street Journal, the benefits could go much further than weight loss.
Continue reading
